Assessing the Safety and Tolerability of NMN in DHDDS-CDG
Part of paid clinical trials in New York, New York.
- Sponsor
- Eva Morava-Kozicz
- Study ID
- NCT07572825
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Congenital Disorder of Glycosylation
- DHDDS-CDG
- DHDDS-Congenital Disorder of Glycosylation
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nicotinamide Mononucleotide (NMN) Nucleosidase — DRUGName: nicotinamide mononucleotide (NMN) Form: measured powder Dose: 250 mg/day Frequency: Daily Route of administration: Oral
Study Details
The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Key Dates
- Start date
- Jun 1, 2026
- Status verified
- May 2026
- Primary completion
- Aug 1, 2027
- Completion
- Aug 1, 2027
Study Design
- Enrollment
- 8 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: nicotinamide mononucleotide (NMN)Participants will take 250mg NMN daily.
Primary Outcome Measure
Incidence of adverse events (AEs) [ Time Frame: up to 12 months ]
Central Contacts
- Georgia MacDonald, MS, CGC646-946-6923
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Eva Morava (PRINCIPAL_INVESTIGATOR) |